

February 18, 2012

Food and Drug Administration
Tobacco Products Scientific Advisory Committee - Notice of Meeting
Docket number FDA-2012-N-0001

Caryn Cohen, M.S.
Center for Tobacco Products
Food and Drug Administration
9200 Corporate Boulevard
Rockville, MD 20850

Email: TPSAC@fda.hhs.gov

The following comment is in response to the February 6, 2012 Federal Register notification (Vol. 77, No. 29, p. 7589) inviting public comment on the January 31, 2012 draft of the “TPSAC Report on Dissolvable Tobacco Products”.

I note that there have been historical concerns about the presence of polonium-210 in smoking tobacco and that the inhalation of the resulting smoke has contributed to lung cancer rates. In the context of the “Additional Product Testing” for “Recommendations for Further Information Gathering, Surveillance, and Research” I would suggest that the polonium-210 content of such dissolvable tobacco products be characterized unless such has already been documented.

Sincerely yours

Mr. Donovan Porterfield

(b) (6)